Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

4.88

Margin Of Safety %

Put/Call OI Ratio

2.14

EPS Next Q Diff

-0.03

EPS Last/This Y

EPS This/Next Y

-0.66

Price

8

Target Price

20.6

Analyst Recom

1

Performance Q

-16.23

Relative Volume

0.59

Beta

1.39

Ticker: ITOS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19ITOS7.242.880.0035072
2024-12-20ITOS7.42.740.2035542
2024-12-23ITOS7.352.760.2535442
2024-12-24ITOS7.472.700.5535389
2024-12-26ITOS7.412.7045.0035400
2024-12-27ITOS7.332.700.4035429
2024-12-30ITOS7.282.660.0135558
2024-12-31ITOS7.692.510.0836146
2025-01-02ITOS7.922.490.0436246
2025-01-03ITOS8.162.470.0236357
2025-01-06ITOS8.082.450.0036410
2025-01-07ITOS7.842.450.0036419
2025-01-08ITOS7.812.440.7836323
2025-01-09ITOS7.812.440.4736323
2025-01-10ITOS7.772.443.3336339
2025-01-13ITOS7.822.44999.9936350
2025-01-14ITOS7.672.440.1736350
2025-01-15ITOS7.772.442.5036370
2025-01-16ITOS7.722.148.3333173
2025-01-17ITOS8.012.140.8933201
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19ITOS7.24-17.8- -3.15
2024-12-20ITOS7.39-17.8- -3.15
2024-12-23ITOS7.35-20.2- -3.15
2024-12-24ITOS7.47-20.2- -3.15
2024-12-26ITOS7.41-20.2- -3.15
2024-12-27ITOS7.33-20.2- -3.15
2024-12-30ITOS7.28-20.2- -3.15
2024-12-31ITOS7.68-20.2- -3.15
2025-01-02ITOS7.92-20.2- -3.15
2025-01-03ITOS8.16-20.2- -3.15
2025-01-06ITOS8.06-20.2- -3.15
2025-01-07ITOS7.85-20.2- -3.15
2025-01-08ITOS7.81-20.2- -3.15
2025-01-09ITOS7.81-20.2- -3.15
2025-01-10ITOS7.76-20.2- -3.15
2025-01-13ITOS7.82-20.2- -3.15
2025-01-14ITOS7.66-20.2- -3.15
2025-01-15ITOS7.77-20.2- -3.15
2025-01-16ITOS7.72-20.2- -3.15
2025-01-17ITOS8.00-20.2- -3.15
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19ITOS0.092.776.38
2024-12-20ITOS0.092.776.38
2024-12-23ITOS0.083.156.38
2024-12-24ITOS0.083.156.38
2024-12-26ITOS0.093.156.18
2024-12-27ITOS0.093.156.18
2024-12-30ITOS0.093.166.18
2024-12-31ITOS0.093.166.18
2025-01-02ITOS0.083.166.18
2025-01-03ITOS0.093.166.18
2025-01-06ITOS0.083.166.18
2025-01-07ITOS0.083.166.18
2025-01-08ITOS0.093.166.18
2025-01-09ITOS0.093.166.18
2025-01-10ITOS0.093.166.18
2025-01-13ITOS0.093.164.88
2025-01-14ITOS0.093.164.88
2025-01-15ITOS0.093.164.88
2025-01-16ITOS0.093.164.88
2025-01-17ITOS0.093.164.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.05

Avg. EPS Est. Current Quarter

-1.02

Avg. EPS Est. Next Quarter

-1.08

Insider Transactions

0.09

Institutional Transactions

3.16

Beta

1.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

26

Growth Score

29

Sentiment Score

29

Actual DrawDown %

84.7

Max Drawdown 5-Year %

Target Price

20.6

P/E

Forward P/E

PEG

P/S

8.35

P/B

0.46

P/Free Cash Flow

EPS

-3.15

Average EPS Est. Cur. Y​

-3.15

EPS Next Y. (Est.)

-3.81

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-346.44

Relative Volume

0.59

Return on Equity vs Sector %

-38.3

Return on Equity vs Industry %

-25.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.22

EBIT Estimation

iTeos Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 157
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
stock quote shares ITOS – ITeos Therapeutics Inc Stock Price stock today
news today ITOS – ITeos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ITOS – ITeos Therapeutics Inc yahoo finance google finance
stock history ITOS – ITeos Therapeutics Inc invest stock market
stock prices ITOS premarket after hours
ticker ITOS fair value insiders trading